Abstract: The present invention is directed to alkoxy tetrahydro-pyridopyrimidine compounds of formula I, which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: The present invention relates to novel compounds, ester pro-drugs of [3-(1-1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals in the treatment of conditions mediated by adrenergic receptors.

Abstract: The present invention relates to electrolyte formulations comprising at least one imidazolium fluorotricyanoborate or pyrrolidinium fluorotricyanoborate and their use in an electrochemical and/or optoelectronic device such as a photovoltaic cell, a light emitting device, an electrochromic or photo-electrochromic device, an electrochemical sensor and/or biosensor, preferably their use in a dye or quantum dot sensitized solar cell.

Abstract: An object of the present invention is to provide a curable epoxy resin composition containing an epoxy resin, wherein the composition is excellent in storage stability and curing characteristics and provides a cured product excellent in characteristics, particularly organic solvent resistance; an adhesive agent consisting of the composition; and an adhesive agent consisting of a curable epoxy resin composition excellent in adhesive strength.

Abstract: The present invention relates to a process for preparing polyisocyanates by oligomerization of isocyanates.

Abstract: The invention provides ?-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred ?-2 agonist used in the inventive compositions and methods is dexmedetomidine.

Abstract: Disclosed are compositions and methods of preparing compositions of active herbicidal ingredients. Also disclosed are methods of using the compositions described herein to improve herbicide delivery and efficacy, enhance herbicidal penetration, reduce herbicide volatility and drift, diminish environmental damage from herbicides, decrease water solubility and volatility of herbicides, and introduce additional biological function to herbicides.

Abstract: A lubricating base oil includes at least one of ionic liquids containing a compound represented by a formula (1): Z+A?, in which Z+ represents a cation and A? represents an anion, in which Z+ is a cyclic quaternary ammonium ion having two different side chains and A? is a conjugated amide ion.

Abstract: A compound of the formula: Wherein A1, A2, X, R2 and R3 are as defined herein, or a composition containing the same, which compound is useful in treating renal-, liver- or pulmonary fibrosis.

Abstract: An inventive electrolyte material contains a lithium salt comprising the following components (A1) and (B), or contains the following components (A1), (A2) and (B): (A1) a lithium cation; (A2) an organic cation; and (B) a cyanofluorophosphate anion represented by the following general formula (1): ?P(CN)nF6-n??(1) wherein n is an integer of 1 to 5. The inventive electrolyte material is excellent in electrochemical properties, i.e., has a higher electrical conductivity and a higher oxidation potential, and is capable of forming an electrode protection film, so that a highly safe lithium secondary battery can be provided.

Abstract: 2-pyridyl substituted imidazoles of the formula (I) as shown in claim 1, are provided, which are useful in the treatment of diseases mediated by ALK5 or ALK4 inhibitors or both.

Abstract: An ionic liquid composition having the following chemical structural formula: wherein R1, R2, R3, and R4 are independently selected from hydrocarbon groups containing at least 1 and up to 20 carbon atoms, and X? is a cyclic anion that possesses a negatively-charged group reactive with a gaseous electrophilic species, particularly carbon dioxide or sulfur dioxide. Methods for capturing a gaseous electrophilic species, such as CO2 or SO2, by contacting the gaseous electrophilic species with an ionic liquid according to Formula (1) are also described.

Abstract: Bipiperidyl compounds of the formula: (I) are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.

Abstract: Compounds of general formula (I), (II), (III) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (III) and (V) in the treatment of kinase-associated disease states is also described. Further described are novel compounds of formula (II), (III) and (V).

Abstract: The present invention relates to a printing composition including an ionic liquid, a printing method using the same, and a pattern formed by using the same. The printing composition according to the exemplary embodiment of the present invention is useful in providing a pattern of a fine line width.

Abstract: Process for preparing salts of the formula I (B+)nxAy? where B is a cation comprising at least one nitrogen atom, A is an anion and n is an integer from 1 to 3, x and y are each an integer from 1 to 3 and the product of x and y is equal to n, by reacting salts of the formula II (B+)nxCy? where B and n, x and y are as defined above and C is a compound which has one or more carboxylate groups (referred to as carboxylate for short) and is different from A, with the ammonium salt of the anion A or with the protic acid of the anion A in the presence of ammonia.

Abstract: The present invention provides Formula (1A) compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. X, Y, Z, R1, R2, R3, and R4 areas described herein.

Abstract: The present invention provides a catalyst composition and a method for preparing an amide. The catalyst composition of the present invention including a hydroxylamine salt, sulfuric acid, and a nitrogen-containing heterocyclic compound is used for catalyzing a ketoxime to form an amide in the Beckman rearrangement reaction. The preparation of an amide by using the catalyst composition of the present invention has high conversion rate of a ketoxime, high selectivity of an amide and high tolerance to water.

Abstract: An electrochromic compound represented by Formula (1), wherein R1 is an alkyl group, an alkenyl group, an aryl group, or a heterocyclic group; R2 and R3 are each a hydrogen atom or a substituent; X is N—R4, an oxygen atom, or a sulfur atom; and R4 is a hydrogen atom or a substituent; provided that at least one of R1-R4 has a partial structure represented by Formula (2), —Si(Y)nR?(3-n)??Formula (2) wherein Y is a halogen atom or OR, R is an alkyl group, or an aryl group; R? is an alkyl group, an alkenyl group, an aryl group, or a heterocyclic group, and n is an integer of 1-3.

Abstract: The present process purifies a salt Cat+X?, where Cat+ is any cation and X? is an organic anion having at least 6 carbon atoms. The salt is an impurity in a composition comprising a water-soluble salt (Cat+)nYn?, where Yn? is an inorganic anion or an organic anion, different from X?, with at most 10 carbon atoms. The process involves converting X? into an acid HX by adding an acid (H+)mZm?, forming two phases: an organic phase comprising HX and an aqueous phase comprising the water-soluble salts (Cat+)mZm? and (Cat+)nYn? or acids (H+)nYn?. The organic phase is separated and the aqueous phase passes over a basic anion exchanger which binds Zm? and Yn? and liberates OH?, giving an aqueous mixture comprising Cat+OH?. The organic phase and the aqueous mixture are converted into Cat+X? and H2O, optionally with addition of further HX.

Abstract: Described herein are compounds of Formula (I): wherein A, J, Z, X, R1 and R4 are defined herein, and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.

Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same. In some embodiments, the present invention provides a compound of formula I-a or I-b: wherein each of Ring A, Ring B, W1, W2, Ry, Rv, Rx, m, p, and R1 is described herein.

Abstract: The present invention relates to electrolyte formulations comprising at least one imidazolium difluorodicyanoborate or pyrrolidinium difluorodicyanoborate and their use in an electrochemical and/or optoelectronic device such as a photovoltaic cell, a light emitting device, an electrochromic or photo-electrochromic device, an electrochemical sensor and/or biosensor, preferably their use in a dye or quantum dot-sensitized solar cell

Abstract: Embodiments are related to ionic liquids and more specifically to ionic liquids used in electrochemical metal-air cells in which the ionic liquid includes sulfonate ions as the anion.

Abstract: The present invention provides Formula (1A) compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. X, Y, Z, R1, R2, R3, and R4 are as described herein.

Abstract: A method and compositions for sulfurizing at least one phosphite or thiophosphite linkage in an oligonucleotide. The addition of N-alkyl imidazole to the acetyldisulfide sulfurization solution enables the use of industrially preferred solvents or solvents that are derived from renewable resources.

Abstract: The application relates to the use of a salt associating an ammonium cation with an alkyl H-phosphonate anion of the following formula (I) in which R is a hydrocarbon radical, the pointed bond can be present or not, the radical R3 being then present or absent, as an ionic liquid. The ammonium cation is preferably an imidazolium cation. This ionic liquid is particularly useful in the field of green chemistry as a substitute for organic solvents. The application also relates to a method for preparing such a salt by the direct dealkylation of the corresponding dialkylphosphite by the appropriate nitrated base, in one step and without any solvent. The application also relates to a method for preparing mixed methylated phosphites.

Abstract: The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

Abstract: Compounds of formula (Ia): wherein R1, R2, R3, R4a, R4b, R5, and R6 are defined herein, as well as other indene derivatives are disclosed herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.

Abstract: The present invention relates to a process for the preparation of compounds with (perfluoroalkyl)fluorohydrogenphosphate anion, and to compounds containing (perfluoroalkyl)fluorohydrogenphosphate anion and to the use thereof.

Abstract: Process for preparing salts K+ X?, where K+ is an organic cation and X? is an anion, by anion exchange, wherein a salt K+ Y?, where K+ is as defined above and Y? is an organic anion having a carboxylate, sulfonate or sulfate group, is used as starting material and K+ Y? is reacted with a hydrogen acid HX whose pKa is less than the pKa of the hydrogen acid HY and after the reaction, the salt K+ X? obtained and the hydrogen acid HY obtained are present in separate liquid phases.

Abstract: Some embodiments described herein relate to ionic liquids comprising an anion of a heteraromatic compound such as optionally substituted pyrrolide, optionally substituted pyrazolide, optionally substituted indolide, optionally substituted phospholide, or optionally substituted imidazolide. Methods and devices for gas separation or gas absorption related to these ionic liquids are also described herein.

Abstract: Process for preparing ionic compounds comprising cations containing quaternary sp2-hybridized nitrogen atoms, which comprises reacting compounds containing a double-bonded nitrogen atom with a dialkyl sulfate with participation of both alkyl groups of the dialkyl sulfate and, if appropriate, subjecting the resulting ionic compound containing sulfate anions to an anion exchange.

Abstract: Methods and small molecule compounds for smoking and CNS disease harm reduction are provided.

Abstract: The invention relates to compounds having the formula: wherein: Q, W, Y, Z, r, and Ar are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

Abstract: The present disclosure provides 2,4-disubstituted thiazoles of the general structure shown below that are agonists of G-protein coupled receptor (IC-GPCR2). Also, provided are compositions comprising these compounds as well as methods for using these compounds in a variety of applications including diabetes and metabolic disorders.

Abstract: The present invention relates to compounds containing organofluorochlorophosphate anions, the preparation thereof and the use thereof, in particular as ionic liquids.

Abstract: Imidazolium monocarboxylate salt compositions are suitable for use as latent catalysts in curable epoxy compositions. The curable compositions prepared therefrom are used to prepare coated substrates, and to produce conformally sealed printed wiring boards. Method for preparation and curing are also provided. Of particular utility are compositions comprising 2-ethyl-4-methyl imidazolium monocarboxylate salts.

Abstract: PROBLEM: Providing a novel ionic liquid, which is low-cost, environment-friendly, and has low viscosity and melting point. MEANS FOR SOLVING THE PROBLEM: The present invention is the invention of the ionic liquid represented by the general formula [1]: {wherein, R1 to R3 and n pieces of R4 each independently represent hydrogen atom or alkyl group having 1 to 4 carbon atoms, R5 to R7 each independently represent alkyl group, aralkyl group, or aryl group, R8 represents alkyl group, aralkyl group, aryl group, or the one represented by the general formula [2]: (wherein T represents alkylene chain having 1 to 8 carbon atoms, n represents 1 or 2, and R1 to R7 are the same as the above-described), X represents nitrogen atom or phosphorus atom, n represents 1 or 2. When n is 1, R3 and R4 are bound and may form cyclohexene ring together with the adjacent carbon atoms. In addition, when X is nitrogen atom, R5 to R7 or R5 to R6 may form hetero ring with nitrogen atom binding thereto}.

Abstract: 1,3-substituted imidazolium salts of the formula I are used as latent catalysts for curing compostions comprising epoxy compounds: in which: R1 and R3 independently of one another are an organic radical having 1 to 20 C atoms; R2, R4, and R5 independently of one another are an H atom or an organic radical having 1 to 20 C atoms, it also being possible for R4 and R5 together to form an aliphatic or aromatic ring; X is the anion of a phosphorus oxyacid, and n is 1, 2 or 3.

Abstract: A non-halogen active agent for a flux is a sulfonate formed by a sulfonic acid reacting with an organic base. The sulfonic acid can be an alkyl sulfonic acid, alkyl disulfonic acid, hydroxyl sulfonic acid or halogenated sulfonic acid. The organic base can be an organic amine, carbamidine, imidazole, phosphorus. The non-halogen active agent for a flux has the advantage of high activity and low corrosion.

Abstract: The present invention relates to quinoxaline compound of the formula (I): wherein R1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R7; R2 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R8; R3, R4, R5 and R6 are each independently hydrogen or R9; and R7, R8 and R9 are each independently selected from organic and inorganic substituents, their use in therapy of diseases, in particular diseases mediated by the tyrosine kinase activity of Janus kinases, including JAK-2 and JAK-3 kinases.

Abstract: A method of synthesizing organic molecules is provided, wherein the method comprises providing an electrophilic educt, providing an ionic liquid comprising a carbanion, and synthesizing the organic molecules by mixing the electrophilic educt and the ionic liquid.

Abstract: The present invention relates to diionic liquid salts of dicationic or dianionic molecules, as well as solvents comprising diionic liquids and the use of diionic liquids as the stationary phase in a gas chromatographic column.

Abstract: The present invention relates to compounds of formula (I), a process for the manufacture thereof, pharmaceutical compositions containing them, and their use for treating CNS disorders: wherein A, B, X, Y, R1, R2, R3 and R4 are as defined in the description and claims.

Abstract: The present invention relates to an improved process for the synthesis of strontium ranelate or hydrates thereof. More particularly, the present invention relates to an effective process for the preparation of a compound of formula III, which is a useful intermediate in the synthesis of strontium ranelate. wherein R1 and R2 represents substituted or unsubstituted linear or branched C1-C6 alkyl group or C3-C12 cyclic group.

Abstract: Boron selective ionic liquids and polymeric ionic liquids, methods of making and methods of using the same are disclosed.

Abstract: Efficient method for preparing the enone intermediate (VII) used in the synthesis of tetracyclines derivatives. In particular, the invention provides a synthesis which allows for substituents at positions 4a, 5, 5a, and 12a of the tetracycline ring system.

Abstract: A method of impeding water input in an ionic liquid is provided, wherein the method comprises adding an additive to the ionic liquid wherein the additive comprises an orthoester. In particular, at least some residues of the additive may remain or may be present in the ionic liquid during the usage of the ionic liquid. For example, the additive may be formed by the orthoester or by a mixture of orthoesters.

Abstract: The present invention relates to diionic liquid salts of dicationic or dianionic molecules, as well as solvents comprising such diionic liquids and the use of such diionic liquids as the stationary phase in a gas chromatographic column.